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Platelets are key elements not only of hemostasis 
and  thrombosis  but  also  of  tissue  regeneration   
after injury and the pathophysiology of inflam-
mation (Gawaz et al., 2005; Nesbitt et al., 2009). 
The  production  of  platelets,  thrombopoiesis,  is 
regulated primarily by thrombopoietin (TPO)-
mediated megakaryopoiesis within the BM   
(Patel et al., 2005; Schulze and Shivdasani, 2005). 
Notably,  many  patients  with  critical  thrombo-
cytopenia, caused by dysregulation of BM as a   
result of hematopoietic disease or aggressive   
chemotherapy, require platelet transfusions using 
platelet concentrates obtained through blood   
donation (Webb and Anderson, 1999). It is   
well known, however, that repeated transfusion 
induces  antibodies  in  recipients  against  allo-
genic human leukocyte antigen (HLA) on the 
transfused platelets (Schiffer, 2001). To establish a 
supply of identical platelet concentrates without 
loss of responsiveness as a result of immunorejec-
tion, particularly for patients with a rare HLA,   
human (h) induced pluripotent stem cells (iPSCs) 
represent a potentially abundant source.
Successful reprogramming of differentiated 
fibroblasts  into  a  pluripotent  stage  using  the   
defined  genes  OCT3/4,  KLF4,  SOX2,  and   
c-MYC (Takahashi et al., 2007; Yu et al., 2007)   
is a potentially effective means of generating   
HLA-matched iPSCs for regenerative medicine   
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Human (h) induced pluripotent stem cells (iPSCs) are a potentially abundant source of 
blood cells, but how best to select iPSC clones suitable for this purpose from among the 
many clones that can be simultaneously established from an identical source is not clear. 
Using an in vitro culture system yielding a hematopoietic niche that concentrates hemato-
poietic progenitors, we show that the pattern of c-MYC reactivation after reprogramming 
influences platelet generation from hiPSCs. During differentiation, reduction of c-MYC 
expression after initial reactivation of c-MYC expression in selected hiPSC clones was 
associated with more efficient in vitro generation of CD41a+CD42b+ platelets. This effect 
was recapitulated in virus integration-free hiPSCs using a doxycycline-controlled c-MYC 
expression vector. In vivo imaging revealed that these CD42b+ platelets were present in 
thrombi after laser-induced vessel wall injury. In contrast, sustained and excessive c-MYC 
expression in megakaryocytes was accompanied by increased p14 (ARF) and p16 (INK4A) 
expression, decreased GATA1 expression, and impaired production of functional platelets. 
These findings suggest that the pattern of c-MYC expression, particularly its later decline, 
is key to producing functional platelets from selected iPSC clones.
© 2010 Takayama et al.  This article is distributed under the terms of an   
Attribution–Noncommercial–Share  Alike–No  Mirror  Sites  license  for  the  first 
six  months  after  the  publication  date  (see  http://www.rupress.org/terms).   
After six months it is available under a Creative Commons License (Attribution– 
Noncommercial–Share Alike 3.0 Unported license, as described at http://creative-
commons.org/licenses/by-nc-sa/3.0/).
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in the proliferation of MK progenitors (Thompson et al., 
1996a,b). Moreover, c-Myc is reportedly essential for the TPO–
c-mpl  axis  in  megakaryopoiesis  (Chanprasert  et  al.,  2006).   
In contrast, recent studies using c-Myc–deficient mice showed 
that the absence of the gene actually led to an increase in the 
platelet count (Guo et al., 2009).
Using a culture system that yields an in vitro hematopoietic 
niche containing hematopoietic progenitors (which we named 
iPS-Sac), we show in this paper that limited reactivation of   
c-MYC and its subsequent decline after a reactivation-dependent 
increase in the gene’s expression in immature MKs are key 
components of platelet generation in vitro and contribute to the 
selection and validation of iPSC clones in which genome inte-
gration is accomplished through reprogramming. These clones 
are suitable for transfusion in clinical applications or mechanistic 
studies of thrombopoiesis using disease-specific iPSCs.
RESULTS
Four-factor hiPSC-derived hematopoietic progenitors 
contribute to enhanced generation of MKs and platelets
Using VSV-G–pseudotyped  retroviruses  (Ory  et  al.,  1996) 
harboring human reprogramming factors (OCT3/4, SOX2, 
(Raya et al., 2009). However, reactivation of c-Myc during es-
tablishment of iPSCs can reportedly lead to oncogenicity after 
transplantation (Okita et al., 2007). But because platelets are 
anucleate, they can be irradiated before transfusion to elimi-
nate residual hiPSCs or other differentiated nucleated cells 
that could form teratomas or malignant tumors (van der Meer 
and Pietersz, 2005). Thus, platelet concentrates derived from 
hiPSCs could be a useful source of HLA-identical platelets, 
which eliminates the need for scarce donor blood. That said, 
because a large number of iPSC clones can be simultaneously 
generated from an identical source, the iPSC clone most suitable 
for the desired purpose must be selected before the differentia-
tion phase (Miura et al., 2009). We therefore sought to determine 
the hallmark of such cells as well as the best way to select iPSC 
clones in vitro for generation of functional platelets in vivo.
c-Myc plays essential roles in both embryonic and adult   
hematopoiesis, although its effects on megakaryopoiesis and 
thrombopoiesis in various mouse models remains unclear 
(Thompson et al., 1996a,b; Chanprasert et al., 2006; Guo et al., 
2009).  For  example,  two  studies  of  inducible  c-Myc  over-
expression (O/E) under the control of megakaryocyte (MK)-
specific differentiation revealed that c-Myc plays a positive role 
Figure 1.  Four-factor human iPSCs are better than three-factor iPSCs for megakaryopoiesis, which is independent of hematopoietic colony 
potential. (A) Numbers of ESC- and iPSC-sac–like structures generated from 105 cells (n = 3, means ± SEM from three independent experiments).  
(B) Numbers of CD34+ hematopoietic progenitors within ESC- or iPSC-sacs yielded from 105 human ESCs or iPSCs (n = 3, means ± SEM). (C) Numbers of 
hematopoietic colonies derived from 105 human ESCs or iPSCs within sacs (n = 3, means ± SEM). (D and E) Numbers of CD42b (GPIb)+ MKs derived from 
105 hematopoietic progenitors within sacs on day 22 (D) and day 26 (E; n = 5, means ± SEM). (F) Representative flow cytometry dot plots for khES-3–, 
TkDN-4-M–, and TkDA3-4–derived MKs examined on day 24.JEM VOL. 207, December 20, 2010 
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To determine the mechanism underlying the enhanced 
megakaryopoiesis exhibited by four-factor hiPSC-derived he-
matopoietic progenitors, we assessed the potential of progenitors 
KLF4, and/or c-MYC), we sought to establish iPSCs from 
human dermal fibroblasts (HDFs). With our system, we con-
sistently generated 200–300 hiPSC clones from 105 HDFs. 
For evaluation of pluripotency, established iPSC clones ob-
tained through transduction with four or three factors (with 
or without c-MYC) and all clones showing a normal karyo-
type (not depicted) were examined for morphology, SSEA-4 
expression (Fig. S1 A), other gene expression (Fig. S1 B), and the 
ability to form teratomas in vivo (Fig. S1 C). Our findings con-
firmed that exogenous OCT3/4, SOX2, KLF4, and c-MYC 
remained unexpressed in established iPSCs (Fig. S1 B).
To explore the hiPSC clones’ potential for differentiation 
into hematopoietic cells (Takayama et al., 2008), we evaluated 
several iPS-Sacs (Fig. S2 A) from individual clones (four-factor 
hiPSCs: TkDA3-1, -2, -4, -5, -9, -20, 201B6, and 201B7; three-
factor hiPSCs: TkDN4-M, 253G1, and 253G4) and compared 
them to previously evaluated human (h) embryonic stem cells 
(ESCs; KhES3 clone, Kyoto University, Japan; Takayama et al., 
2008). On day 15 of culture, iPS-Sacs that contained numer-
ous hematopoietic-like round cells (Fig. S2 B) and showed 
expression of vascular endothelial growth factor type 2 recep-
tor (VEGF-R2+; Fig. S2 B) or platelet endothelial cell adhe-
sion molecule 1 (CD31+; not depicted) were deemed to be 
potentially suitable microenvironments from which to obtain 
hematopoietic progenitors, as was observed in hESC-derived 
structures (Takayama et al., 2008).
We detected considerable heterogeneity in the produc-
tion of iPS-Sacs (a hallmark of the efficiency of hematopoi-
etic progenitors) from iPSCs derived from the same source 
(i.e., TkDA3-1, -2, -4, -5, -9, or -20; Fig. 1 A), which was also 
consistent with previous observations in hESCs (Osafune   
et al., 2008). In particular, CD34+, but not CD34, cells from 
iPS-Sacs showed successful colony formation in methylcellu-
lose colony assays (Fig. S2 C). The three-factor clone TkDN4-M, 
as well as KhES-3, appeared to have a greater potential for 
myeloid lineage hematopoiesis, as exemplified by the num-
bers of Sacs (Fig. 1 A, red bar) composed of CD34+ cells   
(Fig. 1 B, red bar), and the numbers of hematopoietic colonies 
formed from each Sac (Fig. 1 C, red bar). Nonetheless, the 
number of CD42b (GPIb; von Willebrand factor receptor)+ 
MKs obtained with four-factor iPSC clones (e.g., TkDA3-2, 
TkDA3-4, and TkDA3-5) was higher than that obtained with 
TkDN4-M or KhES-3 when equal numbers of cells from 
iPS-Sacs were seeded onto fresh culture dishes in the pres-
ence of TPO, stem cell factor (SCF), and heparin (Fig. 1, D 
[day 22] and E; and Fig. S3 day 26; Takayama et al., 2008). For 
example, clone TkDA3-4 generated three times as many MKs 
as TkDN4-M or KhES-3 at the peak of production (Fig. 1 E, 
day 26; and Fig. S3). By days 22–38, phase-contrast imaging 
revealed the presence of proplatelets, a prerelease platelet form 
(Video 1), as well as mature MKs by May-Giemsa staining 
(Fig. S4). Moreover, flow cytometric analysis showed that   
40–60% of floating cells expressed CD41a (integrin IIb3 
complex), a fibrinogen receptor, as well as CD42a (GPIX), 
GPIb, and CD9, all of which are hallmarks of MKs (Fig. 1 F; 
Tomer, 2004; Takayama et al., 2008).
Figure 2.  Time-dependent changes in qPCR induced by exogenous 
reprogramming genes in three-factor or four-factor iPSCs. mRNA 
encoding exogenous OCT3/4 (A), SOX2 (B), KLF4 (C), and c-MYC (D) in 
human ES cells (ESCs), TkDN4-M (three-factor iPSCs), TkDA3-2, TkDA3-4, 
and TkDA3-5 (four-factor iPSCs) on day 0 or their derivatives (on days 6, 
10, 15, 22, and 26 after initiation of MK-lineage culture) were examined 
by qPCR as described in the Materials and methods section. TkDA3-4–
derived mature MKs (day 26) was assigned a value of 1.0 (n = 4, means ± 
SEM from two independent experiments).2820 c-MYC modulates platelet generation from iPSCs | Takayama et al.
MK lineage culture) revealed expression of the exogenous 
(transgene [Tg]) reprogramming genes, which were not ex-
pressed before hematopoiesis (Fig. 2, A–D, day 0; and Fig. S1 B). 
Although qPCR after day 15 suggested that, in four-factor 
iPSCs, activation of OCT3/4 Tg and/or c-MYC Tg might affect 
the enhanced megakaryopoiesis (Fig. 2, A and D), individual 
Tg activation was not dependent on the copy number in the 
genome (Fig. S1, D and E).
Thus, to confirm the functional effect of OCT3/4 and/or 
c-MYC Tg on megakaryopoiesis from pluripotent stem cells, 
within iPS-Sacs, based on colony-forming capacity (Fig. S2 D) 
and their surface markers (not depicted). We found no signifi-
cant differences between TkDA3-4 (four-factor) and TkDN4-M 
(three-factor; Fig. S2 D), which means the potential and the 
capacity to drive most myeloid lineage commitment from 
iPSC-derived progenitors is independent of the clone type, or 
at least there was no detectable difference between the three- 
and four-factor iPSC clones we examined (not depicted).
In contrast, quantitative (q) PCR analysis of hematopoi-
etic cells on days 22–26 (7–11 d after replating for selective 
Figure 3.  Effects of reprogramming factors on megakaryopoiesis. (A–C) Each reprogramming factor was transduced, together with EGFP or KO 
markers, on day 15 of MK-lineage culture. Numbers of total and marker genes EGFP or KO-expressing cells in floating cells on day 17 (A) and CD42b+ MKs 
on days 22 (B) and 26 (C) were measured (n = 3, means ± SEM). (D) Representative flow cytometry dot plots of hESC-derived hematopoietic cells trans-
duced with vehicle (EGFP), OCT3/4-KO, SOX2-EGFP, KLF4-EGFP, or c-MYC-EGFP on day 22. (E and F) On day 22, May-Giemsa staining (E) or ploidy analysis (F) 
of the cells transduced with vehicle or c-MYC was examined.JEM VOL. 207, December 20, 2010 
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c-MYC levels in hiPSC-derived MKs 
determines the number of platelets 
generated per MK
We  next  tested  whether  iPSC- 
derived MKs actually yield platelets 
in vitro. We confirmed that four-factor 
iPSCs generate greater numbers of 
platelets than three-factor iPSCs or 
hESCs (Fig. 4, A and B; and Fig. S5). 
Moreover,  we  noticed  that,  at  the 
peak of production (day 26), many 
more proplatelets and platelets were 
generated from TkDA3-4 iPSCs than 
from  any  other  four-factor  iPSCs 
(Fig. 4, B and C; and Fig. S5). We also 
noted that TkDA3-2 and TkDA3-5 
iPSC-derived MKs showed an ear-
lier peak, on day 22 (Fig. 1, D and E; 
and  Fig.  S3)  and  that  there  were 
fewer proplatelets in the dishes (Fig. 4 C), which suggests that 
most MKs promote apoptosis and/or senescence leading to 
inhibition of platelet release in those two clones.
It has been reported that forced expression of c-Myc impairs 
maturation of MKs displaying polyploidization, leading to an 
increase in immature MKs (Thompson et al., 1996a). Indeed, we 
confirmed the appearance of immature MKs (Fig. 3, D–F) 
on day 22 after retroviral transduction of c-MYC into hESC- 
derived hematopoietic progenitors, which diminished proplatelet 
formation and platelet yield (Fig. 4, C and D; and Fig. S6 A). 
Dot plots for CD41a+CD42b+ platelets obtained by flow cyto-
metric analysis of KhES-3, TkDN4-M (three-factor iPSCs), 
and TkDA3-4  (four-factor  iPSCs)  showed  similar  patterns   
(Fig. 4 E and Fig. S6 A), although most of the CD41a+CD42b 
platelets appeared to have shed the extracellular domain of 
each reprogramming factor was separately introduced into   
hematopoietic progenitors derived from KhES-3, along with 
EGFP or Kusabira orange (KO), which served as markers. 
Only c-MYC expression recapitulated the time course of the 
enhanced megakaryopoiesis, as it was accompanied by greater 
transduction efficiency as a result of the increased cell prolifer-
ation it induced (Fig. 3, A–C). Flow cytometry revealed that 
on  day  22,  most  of  the  EGFP+  or  KO+  population  was 
CD41a+CD42b+ in the c-MYC O/E specimens but not in the 
others (Fig. 3 D), although only mononuclear and lower ploidy 
cells were present (Fig. 3, E and F). These suggest that OCT3/4 
O/E might not accelerate megakaryopoiesis (Fig. 3 D). Col-
lectively then, these findings suggest that stronger expression 
of c-MYC in hESCs might promote lineage commitment into 
megakaryopoiesis without maturation.
Figure 4.  Level of c-MYC reactivation 
in individual iPSC-derived MKs may de-
termine the efficiency of platelet gen-
eration in vitro. (A and B) Numbers of 
CD41a+CD42b+ platelets generated from 
hESCs or hiPSCs on days 22 (A) and 26 (B; 
peak of platelet generation; n = 5, means ± 
SEM). (C and D) Numbers of proplatelets  
(C) and platelets (D) derived from four-
factor iPSCs and from ESC hematopoietic 
progenitors, with or without c-MYC trans-
duction (ii; n = 5, means ± SEM). Represen-
tative photomicrographs of proplatelets are 
derived from four-factor iPSCs. (D) Numbers 
of platelets per MK was calculated as the 
total number of platelets divided by the 
total number of MKs on day 26 (n = 5, 
means ± SEM). (E) Representative flow cy-
tometry dot plots show MKs derived from 
TkDA3-4 and KhES-3, with or without  
c-MYC transduction, on day 26.2822 c-MYC modulates platelet generation from iPSCs | Takayama et al.
c-MYC  and  the  genes  involved  in   
c-MYC activation and thrombopoiesis. 
qPCR analyses confirmed that total 
(endogenous plus exogenous) c-MYC 
expression  in TkDA3-4, TkDA3-5, 
and c-MYC-O/E hESCs (KhES-3) 
was  higher  than  in  TkDN4-M 
(three-factor)  or  hESCs  without   
c-MYC (control) on days 15 (hema-
topoietic progenitors) and 22 (im-
mature MKs) of culture (Fig. 5 A). 
Intriguingly, however, total c-MYC 
expression  in  TkDA3-5  increased 
progressively from days 15 through 
26, whereas in TkDA3-4, the iPSC 
clone  showing  the  most  efficient 
platelet  generation,  total  c-MYC  
expression  declined  after  day  15 
(Fig. 5 A). To confirm whether reactivation actually influ-
enced total c-MYC expression (Fig. 5 A), we separately ex-
amined endogenous and exogenous (Tg) c-MYC expression. 
We found that although levels of total and exogenous c-MYC 
differed among the clones (Fig. 5 A and Fig. S7 A), there was 
no significant difference in endogenous c-MYC levels among 
TkDN4-M, TkDA3-4, and TkDA3-5 (Fig. S7 B). In contrast, 
expression of two INK4A locus genes, p14 (ARF) and p16 
(INK4A), which act as a safety net system against c-Myc hyper-
activation leading to senescence (Murphy et al., 2008), was 
higher in c-MYC-O/E hESCs and TkDA3-5 than in TkDA3-4 
on day 22 (immature MKs; Fig. 5, B and C). We therefore as-
sumed that elevation of p14 and p16, beginning at an earlier 
phase of differentiation, is associated with inhibition of MK 
maturation (Fig. 3, E and F). MYC associates with the GATA1 
promoter during immature erythroblast expansion, perhaps 
suppressing GATA-1 expression (Rylski et al., 2003). Similarly, 
CD42b (GPIb), as indicated by the recovery of CD42b 
expression in the presence of a metalloprotease inhibitor   
(Fig. S6 B; Nishikii et al., 2008). In contrast, platelet-like par-
ticles from hESC-derived MKs ectopically expressing c-MYC 
(c-MYC-O/E) showed significantly lower CD42b expression, 
a distinct pattern on dot plots (Fig. 4 E and Fig. S6 A), and no 
recovery of CD42b expression after administration of metallo-
protease inhibitor (not depicted). Given the platelet generation 
per MK, it appears that forced expression of c-MYC in ESCs 
impairs platelet yield on day 26 (Fig. 4 D), which might re-
capitulate in TkDA3-2 or TkDA3-5 iPSC-MKs (Fig. 4 D).
How does the level of c-MYC expression control platelet 
generation from iPSCs?
The results so far suggest that excess c-MYC expression di-
minishes platelet yield. To confirm that hypothesis, we evalu-
ated the time-dependent changes in the total expression of 
Figure 5.  Level of c-MYC expression 
affects INK4A/ARF locus genes and genes 
related to MK maturation during mega-
karyopoiesis from pluripotent stem cells. 
qRT-PCR analysis of total c-MYC (A, endog-
enous plus exogenous), p14ARF (B), 
p16INK4A (C), GATA1 (D), 1-tubulin (E), and 
NF-E2 p45 (F) expression in hESCs, with and 
without overexpression (O/E) of exogenous  
c-MYC, on days 22 and 26 (7 and 11 d  
after transduction) in three-factor hiPSCs 
(TkDN4-M) or in four-factor hiPSCs (TkDA3-4 
and TkDA3-5) on days 0, 15, 22, and 26. All 
levels were normalized to the level of GAPDH 
expression (n = 4 of two independent  
samples). The levels of c-MYC (A), p14ARF (B), 
and p16INK4A (C) expression in an undiffer-
entiated TkDA3-4 iPSC clone (day 0) or  
expression of the other genes (D–F) in 
TkDA3-4–derived mature MKs (day 26) was 
assigned a value of 1.0 (n = 4, means ± SEM).JEM VOL. 207, December 20, 2010 
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Inducible c-MYC expression in iPSCs 
without reactivation exhibited behavior 
similar to that of iPSCs with 
reactivation, leading to efficient 
generation of functional platelets
To  further  confirm  whether  an  in-
crease and subsequent decline in c-MYC is critical for mega-
karyopoiesis, leading to an efficient platelet yield, we prepared 
a Sendai viral vector (SeV) harboring the four reprogram-
ming genes, which, during the generation of human iPSCs, 
enabled RNA viral transduction without integration of DNA 
into the chromosome (Nishimura et al., 2007; Fig. 6, A and B). 
Thereafter, doxycycline (DOX)-inducible expression system 
in a lentiviral vector was applied to the SeV-based human   
iPSCs  (SeV-iPSCs;  skin-fibroblast  [HDF]-derived  SeV-iPSCs 
and cord blood [CB] CD34+ cell-derived SeV-iPSCs; Fig. 6 A). 
We selected CB-derived SeV-iPSCs (clone 2; Fig. 6, A and B) 
for most experiments because they showed no detectable Tg 
and better differentiation to hematopoietic progenitors than 
other  clones,  including  HDF-derived  SeV-iPSCs  (not  de-
picted). c-MYC O/E was regulated by DOX (Fig. 6 C), and 
GATA-1  expression  was  reduced  in  c-MYC-O/E  hESC   
(KhES-3)-MKs showing higher levels of c-MYC expression 
on day 22, as were levels of 1-tublin and NF-E2 (p45; Fig. 5,   
D–F). Consistent with those findings, both c-MYC-O/E MKs 
and TkDA3-5–derived MKs showed less proplatelet formation 
(Fig. 4 C) and had a smaller platelet yield than TkDA3-4 
(Fig.  4  D). Thus,  high  levels  of  sustained  expression  of   
INK4A locus genes in MKs are also associated with impaired 
platelet release.
These results suggest that an increase in c-MYC expres-
sion, peaking on day 22, followed by a decline may be critical 
for efficient platelet generation on day 26, as exemplified in 
TkDA3-4. Sustained increases in c-MYC expression may con-
tribute to activation of senescence genes, thereby impairing 
MK maturation and intact platelet yield.
Figure 6.  Inducible c-MYC expression 
system enabling Sendai viral vector–based 
iPSCs without reactivation to recapitulate 
enhanced MK maturation with increased 
platelet generation. (A) Representative pho-
tomicrographs of SeV-iPSCs derived from CB 
CD34+CD45+ cells or HDFs. Original magnifi-
cation, 100×. (B) RT-PCR analyses of Sendai 
virus Tg (harboring reprogramming factors) 
expression in SeV-iPSC clones (passage num-
ber 4) derived from CB, HDF-A (adult), and 
HDF-N (neonate). A sample of HDFs trans-
duced with SeV is used as a positive control 
for the SeV Tg. (C) Scheme of c-MYC induc-
tion in SeV-iPSC–derived hematopoietic cells. 
Hematopoietic progenitors derived from SeV-
iPSCs were transfected with DOX-inducible  
c-MYC O/E vector on day 15 and analyzed on 
day 26. In Protocol a, DOX was added only 
from days 15 to 22. In protocol b, DOX was 
added from days 15 through 26. (D) Repre-
sentative Western blots of cell lysates with  
c-MYC O/E (DOX-on; protocol b) or without  
c-MYC O/E (DOX-off; Protocol a) on day 26. 
The -tubulin levels indicate same protein 
value. (E–G) Numbers of CD42b (GPIb)+ MKs 
(E), proplatelets (F), and platelets (G) on day 
26 derived from 105 hematopoietic progeni-
tors transfected with vehicle or DOX-inducible 
c-MYC O/E vector in protocol a or protocol b 
(n = 4, means ± SEM). (H) Numbers of plate-
lets per MK generated on day 26 of culture 
(peak of platelet generation; n = 4, means ± 
SEM). Numbers of platelets per MK were cal-
culated as the total number of platelets di-
vided by the total number of MKs on day 26.2824 c-MYC modulates platelet generation from iPSCs | Takayama et al.
integrin activation in human platelets (from 
peripheral  blood  [PB]),  PB-based  aged 
platelets (48-h incubation; Bergmeier et al., 
2003; Nishikii et al., 2008), iPSC platelets, 
and ESC platelets. The aged platelets were 
tested because iPSC-derived platelets were 
heterogeneously produced from MKs at 
various stages in culture, so that many of 
the platelets produced could have become 
aged (Nishikii et al., 2008). Conforma-
tional  changes  in  integrins  are  required 
for platelet aggregation and stable throm-
bosis in vivo (Shattil et al., 1985). Indeed, 
although  PB-based  aged  platelets  were 
nonresponders,  the  integrin  activity  of 
TkDA3-4 (four-factor iPSCs) platelets was comparable to 
that  of  TkDN4-M  (three-factor  iPSCs)  platelets,  which 
showed a weaker response than human PB platelets (Fig. 7,   
A and B; and Fig. S8 A). Notably, c-MYC O/E-dependent 
iPSC-derived platelets showed little binding (Fig. 7, A and B). 
In  contrast,  platelets  produced  from  SeV-iPSCs-MKs  in   
the absence of c-MYC O/E after its activation responded 
well to ADP stimulation (Fig. 7 C). We therefore conclude 
that c-MYC activation and decline during MK differentia-
tion may lead to the generation of functional platelets from 
iPSCs. We also examined expression of P-selectin (CD62P) 
on platelets in the presence of 50 µM ADP and observed 
weak but positive P-selectin expression in iPSC-derived 
platelets (Fig. S8 B).
we confirmed that day 22 was the most suitable point to turn 
off O/E. The results also showed that continuous c-MYC O/E 
from days 22 to 26 still increased the number of MKs (Fig. 6 E), 
whereas the lack of c-MYC O/E from days 22 to 26 increased 
the total numbers of proplatelets (Fig. 6 F) or CD41a+CD42b+ 
platelets (Fig. 6 G). An increase in platelet yield per MK   
was also evident with the absence of c-MYC O/E after   
day 22 (Fig. 6 H), confirming the effect of c-MYC expression 
on megakaryopoiesis.
Human iPSC-derived platelets function normally in vitro 
and in vivo
To assess the effect of c-MYC reactivation on the functional-
ity of platelets from TkDA3-4, we compared agonist-induced 
Figure 7.  Integrin activation and the struc-
ture of human iPSC platelets are comparable 
to those in human PB-derived platelets.  
(A–C) Integrin activation in fresh human platelets 
(Fresh-P), aged human platelets (48-h incubation 
at 37°C; Aged-P), TkDN4-M (three-factor iPSC) 
platelets (3f-iPSC-P), TkDA3-4 (four-factor iPSC) 
platelets (4f-iPSC-P), and ESC platelets (ESC-P), 
with or without c-MYC O/E. The binding of PAC-1 
(indicative of platelet activation) to individual 
platelets was quantified in the absence and pres-
ence of 50 µM ADP using flow cytometry. (A) Rep-
resentative flow cytometry dot plots. Square 
indicates CD42b+ platelets. (B) Mean fluorescence 
intensity (MFI) of bound PAC-1, obtained from 
square gate in A. Error bars depict means ± SEM 
for four independent experiments (duplicate).  
(C) Representative flow cytometry analysis of PAC-1– 
bound platelets generated from integration-free 
SeV-iPSCs subjected to biphasic activation and, 
thereafter, decline of c-MYC expression as protocol b 
shown in Fig. 6 C. Square indicates CD42b+ plate-
lets. (D) Spreading of iPSC platelets on fibrinogen. 
Human CD41a (red) and phalloidin (green) were 
used to identify F-actin fibers. Arrowheads indicate 
lamellipodia. Arrows indicate actin stress fibers. 
Bars, 5 µm. (E) Transmission electron micrographs 
of hiPSC (TkDA3-4) platelets on day 26. Bar, 3 µm.JEM VOL. 207, December 20, 2010 
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In  contrast,  as  in  the  previous 
paragraph, we recently showed that 
culture at 37°C influences the degra-
dation of platelets by causing them 
to  shed  the  extracellular  domain   
of  GPIb,  which  is  required  for   
initial adhesion to the injured ves-
sel  wall  (Nishikii  et  al.,  2008;   
Fig. S6 B). In vivo, platelets lacking 
the GPIb extracellular domain are 
quickly cleared from the circula-
tion (Bergmeier et al., 2003), leading 
to insufficient levels of circulating platelets after transfusion 
(Nishikii et al., 2008). To avoid this without affecting platelet 
yield, we applied GM6001, a nonspecific inhibitor to metal-
loproteases, for 2 d before collection of cultured platelets and 
confirmed that the shedding of GPIb was dose-dependently 
inhibited by GM6001 (Fig. S6 B; Nishikii et al., 2008).
We next sought to develop a transfusion model to assess 
platelet circulation in vivo. Using a NOG (nod-scid/IL-2 c-
null) mouse thrombocytopenia model induced by irradiation 
(2.0 Gy, 9 d beforehand), flow cytometric analyses performed 
TkDA3-4 iPSC platelets on immobilized fibrinogen ex-
hibited filopodia, lamellipodia, and/or actin stress fibers, all of 
which are also indicative of platelet thrombosis (Shattil et al., 
1985; Fig. 7 D), suggesting that appropriate elevation and then 
reduction of c-MYC expression increases production efficiency 
without impairing platelet functionality, at least in vitro. More-
over, the granule content and structural components of TkDA3-4 
iPSC platelets appeared normal when examined under trans-
mission electron microscopy (Fig. 7 E), which implies a capacity 
for hemostasis in vivo.
Figure 8.  Human iPSC platelets circu-
late in NOG mice and adhere to vessel 
during thrombus formation in vivo.  
(A) NOG (nod-scid/IL-2 c-null) mice were 
irradiated (2.0 Gy) to induce thrombocyto-
penia. 9 d later, human iPSC platelets,  
human PB-derived platelets (107), or PBS 
alone was injected via the tail vein. Platelet 
chimerism was quantified by flow cytom-
etry. Representative dot plots for the same 
experiment are shown. Circulation of in-
jected platelets was evaluated after 2 and 
24 h (orange squares). Experiments were 
independently performed three times.  
(B) Sequential images of circulating iPSC 
platelets. A combination of FITC-dextran 
(green) and 107 TMRE-stained iPSC plate-
lets (red) in PBS was injected via the tail 
vein into NOG mice. Mesenteric capillaries 
were visualized using a confocal laser-
scanning microscope. Red arrows indicate 
circulating iPSC platelets in vivo. Original 
videos are available as Video 2. (C) Repre-
sentative sequential images of thrombus 
formation by iPSC platelets in a blood ves-
sel. Hematoporphyrin was administrated to 
induce thrombus formation after laser-
induced injury, as described previously 
(Nishimura et al., 2008; Takizawa et al., 
2010). Red arrows indicate iPSC platelets in 
a developing thrombus. White arrows indi-
cate host (mouse) platelets. Original videos 
are available as Videos 3–5. Experiments 
were independently performed three times. 
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number of platelets per MK derived from individual four-factor 
hiPSC clones (TkDA3-2, -4, and –5; with c-MYC) and ESCs 
(with or without c-MYC) on day 26 differs (Fig. 4 D). None-
theless, TkDA3-4, which is the most efficient platelet-producing 
clone (Fig. 4, B and D; and Fig. S5), shows weaker c-MYC ex-
pression than other four-factor iPSCs or c-MYC-O/E MKs 
(Fig. 5 A). Indeed, DOX-inducible expression of c-MYC O/E 
in  genome  integration-free  iPSCs  (SeV-iPSCs)  confirmed 
our hypothesis (Fig. 6, A–H). In addition, when we considered 
the possibility that deregulated MK maturation leads to release 
of nonfunctional platelets, we found differences in platelet 
functionality between hESCs or SeV-iPSCs, with or without 
c-MYC, and iPSC clones (Fig. 7, A–C). Immature megakaryo-
cytic cell lines, such as Meg01, are reportedly capable of releas-
ing  CD41a+  platelet-like  particles,  but  they  show  poor 
functionality in vitro (Takeuchi et al., 1998). We also found that 
hESC-derived CD41+ particles showed significantly less CD42b 
expression when c-MYC was ectopically expressed in MKs   
(Fig. 4 E and Fig. S6 A) and showed poor functionality in vitro 
(Fig. 7, A and B). In contrast, the function of CD42b+ platelets 
generated from TkDA3-4 was intact and able to mediate he-
mostasis in vivo, although some of the yield was likely made 
up of nonfunctional aged platelets (Fig. 7 and Fig. 8 C).
To clarify the underlying mechanism, we examined the 
association between platelet generation and gene expression. 
In c-MYC-O/E MKs, expression of GATA1 (Vyas et al., 1999; 
Rylski et al., 2003), a key regulator for MK maturation and 
polyploidization, was suppressed, whereas INK4A and ARF 
expression  was  greatly  up-regulated  (Fig.  5,  B–D;  Eischen   
et al., 1999; Murphy et al., 2008). Consequently, the maturation 
phase was inhibited, as exemplified by the presence of hypo-
ploid cells without proplatelets (Fig. 3, E and F; and Fig. 4 C) 
and the weak expression of mature MK markers 1-tubulin 
and NF-E2 (Fig. 5, E and F), as well as platelet factor 4 (not de-
picted; Patel et al., 2005; Schulze and Shivdasani, 2005). These 
MKs only generated a few nonfunctional CD41a+CD42b+ 
platelets (Fig. 4, D and E; Fig. 5 A; and Fig. 7 B). In contrast, 
MKs derived from TkDA3-4 transiently showed appropri-
ately high levels of c-MYC expression, with no effect on ex-
pression of INK4A/ARF locus genes (Fig. 5, A [day 15], B, 
and C), after which c-MYC expression declined (Fig. 5 A, days 
22 and 26). From days 22 to 26, the pattern of GATA1, 1-
tubulin, and NF-E2 expression was opposite that of c-MYC 
expression (Fig. 5, D–F), indicating that reduction of c-MYC 
after day 22 (immature MKs) may be required for MK matu-
ration and generation of functional platelets (e.g., day 26).   
We therefore suppose that because most MKs derived from 
TkDA3-5,  which  produced  fewer  platelets  than TkDA3-4 
(Fig. 4 D), showed sustained c-MYC activity, leading to up-
regulation of INK4A/ARF locus genes (Fig. 5), those MKs 
were unable to complete the maturation phase, even though 
GATA-1, 1-tubulin, and NF-E2 expression was enhanced 
(Fig. 5, D–F). We further confirmed this phenomenon using 
integration-free SeV-iPSCs in a DOX-inducible gene expres-
sion system. Removal of c-MYC O/E from day 22 until day 
26 increased the total numbers of proplatelets (Fig. 6 F) and 
2 and 24 h after transfusion (1.0–1.2 × 107 platelets/mouse) 
showed that four-factor iPSC platelets were consistently pres-
ent and that the percentage circulating was similar to that   
obtained with fresh human platelets (platelet chimerism of 
human CD41a+/mouse CD41a+; 3–10%, 2 h after transfu-
sion; Fig. 8 A).
To further assess and confirm the functionality of TkDA3- 
4 hiPSC platelets in vivo, we used the same NOG mouse 
model (Fig. 8 A) with high–spatiotemporal resolution confo-
cal laser microscopy to visualize the behavior of individual 
platelets upon initiation of adhesion to an injured vessel wall 
and during the subsequent steps in thrombus formation   
under flow within the vessel (Takizawa et al., 2010). iPSC 
platelets stained with tetramethylrhodamine ethyl ester, which 
is incorporated into the external lipid layer of the cell mem-
brane, were transfused into NOG mice (2 Gy, 14 d before-
hand), after which we confirmed they circulated as individual 
platelets (Fig. 8 B, red; and Video 2). Then using our novel   
laser injury thrombus model (Takizawa et al., 2010), we clearly 
observed that iPSC platelets initially adhered to the injured 
vessel wall, coordinating with host platelets and ultimately 
leading to thrombus formation and vessel occlusion (Fig. 8 C; 
and Videos 3–5). Thus, four-factor iPSC platelets appear capa-
ble of mediating hemostasis and thrombosis in vivo.
DISCUSSION
Megakaryocytic lineage-restricted c-Myc expression in mouse 
models showed this gene to be a positive regulator of MK 
progenitor proliferation (Thompson et al., 1996a,b) and to be 
required  for  TPO/c-mpl  signaling  in  megakaryopoiesis 
(Chanprasert et al., 2006). Notably, c-Myc deficiency also ac-
celerates megakaryopoiesis, but with lower ploidy (up to 8n), 
and augments immature platelet release accompanied by an 
increase in the platelet count. In our hiPSC culture system, 
however, total cellular c-MYC expression (endogenous plus 
reactivation of exogenous) appeared to be at an appropriate, 
and probably restricted, level suitable for promoting platelet 
generation (Fig. 4 B, Fig. 5 A, and Fig. 6 G, day 26). Increasing 
MYC levels enables cells to move from quiescence to S phase, 
even in the absence of mitogens (Eilers et al., 1991), possibly 
through activation of target genes (cyclin D1(D2,D3)/Cdk4(6) 
and cyclin E/Cdk2). In that regard, although MYC activity, per 
se, is required for normal cell proliferation (Murphy et al., 
2008), it is recognized that above a certain threshold c-Myc 
expression may induce the onset of oncogenesis. Moreover, 
excessively high MYC levels induce senescence via activation 
of the Arf–Mdm2–p53 pathway (Eischen et al., 1999; Murphy 
et al., 2008) and suppression of key regulators of MK matura-
tion, such as GATA1, 1-tubulin, and NFE2, which likely   
inhibits maturation (Fig. 5, B–F) and may also induce apopto-
sis in some cells (Askew et al., 1991; Evan et al., 1992).
Four-factor  hiPSC-derived  hematopoietic  progenitors 
also generate much larger numbers of platelets than three-
factor iPSCs or hESCs (Fig. 4, A and B; and Fig. S5), possibly 
as a result of MK proliferation mediated though c-MYC reac-
tivation (Fig. 3 A; Fig. 4, A and B; and Fig. S3). However, the JEM VOL. 207, December 20, 2010 
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The mouse C3H10T1/2 cell line was purchased from the Institute of Physi-
cal and Chemical Research Bio-Resource Center (Tsukuba, Ibaraki, Japan) 
and was cultured as described previously (Takayama et al., 2008). Retroviral 
supernatants for establishing iPSCs were obtained from a 293 GPG system 
(provided by R.C. Mulligan, Children’s Hospital Boston, Boston, MA; Ory   
et al., 1996). SeV vector harboring human OCT3/4, SOX2, KLF4, and   
c-MYC was based upon original SeV vector and viral supernatants were made 
as previously described (Nishimura et al., 2007). Another set of hiPSCs with-
out genome integration was established using SeV harboring four factors 
from HDFs or CB CD34+/CD45+ cells (Lonza). Hematopoietic differentia-
tion from iPSCs and hESCs was performed in the same medium, as described 
previously (Takayama et al., 2008). The following antibodies were used: PE-
conjugated anti-CD9, PE-conjugated anti-CD31, PE- or FITC-conjugated 
anti-CD34,  unconjugated  or  allophycocyanin  (APC)-conjugated  anti-
CD41a (HIP8 clone), FITC-conjugated anti-CD42a, PE-conjugated anti-
CD42b,  Alexa  Fluor  405–conjugated  anti-CD45,  and  APC-conjugated 
anti–VEGF-R2. FITC-conjugated PAC-1 (BD) and FITC-conjugated anti-
CD62P (P-selectin; BioLegend) antibodies were used for platelet activation 
studies (Shattil et al., 1985). Tirofiban (Takayama et al., 2008), a specific an-
tagonist of human integrin IIb3, was obtained from Merck. Anti–c-Myc 
(1:400; Santa Cruz Biotechnology, Inc.), anti–-tubulin (1:1,000; Sigma- 
Aldrich), anti–mouse IgG-HRP (1:5,000; GE Healthcare), and anti–rabbit 
IgG-HRP (1:2,500; GE Healthcare) antibodies were used for Western blot-
ting. 15-wk-old NOG mice were obtained from the Central Institute for 
Experimental Animals (Kanagawa, Japan) and were maintained under specific 
pathogen-free conditions. The mice were irradiated at 2.0 Gy to induce 
thrombocytopenia and have analyzed for platelet chimerism using an Aria 
flow cytometer (BD) or by in vivo imaging using a confocal laser-scanning 
microscope (CSU-X1; Yokogawa Electronics).
Induction  of  human  iPSCs  using  high-titer  retroviruses  or  SeV   
viruses. hiPSCs were established from HDFs using high-titer retroviruses 
derived from 293GPG cells (Ory et al., 1996). Integration-free human iPSCs 
were established with SeV harboring human OCT3/4, SOX2, KLF4, and   
c-MYC as described in the previous section. CB cells were infected with SeV 
in the same basal medium (Takayama et al., 2008) supplemented with 50 ng/ml 
human SCF (R&D Systems), human TPO (R&D Systems), and human 
FMS-related tyrosine kinase 3 ligand (FLT3-L; PeproTech).
Immunohistochemistry of human ESCs and human iPSCs. hiPSCs 
were fixed with 4% paraformaldehyde in PBS, after which they were labeled 
first with an antibody against human SSEA4 (Millipore) and then with a sec-
ondary antibody and observed using an epifluorescence microscope (DM 
IRBE; Leica).
Semi-qRT-PCR. hiPSCs were lysed with Trizol (Invitrogen), after which 
total RNA was extracted as recommended by the manufacturer. Comple-
mentary DNAs were obtained using an RT-PCR System (Thermo Fisher 
Scientific) and oligo-dT primers (Invitrogen). Samples were normalized to 
intrinsic GAPDH. Semi-qRT-PCR was performed to determine the expres-
sion levels of genes of interest. Amplification proceeded for 26–32 cycles.   
The primer sets used are shown in Table S1.
Teratoma formation and histological analysis. hiPSCs were prepared 
from 107 cells/ml in PBS. Male NOD/Scid mice were anesthetized with di-
ethyl ether, after which aliquots of suspended cells (1–3 × 106 cells) were in-
jected into their testes. 8 wk after injection, the mice were sacrificed, and the 
resultant tumors were dissected. Tumor samples were then fixed in 4% para-
formaldehyde, embedded in paraffin, sectioned, and stained with hematoxy-
lin and eosin.
Southern blotting analysis. 7 µg of genomic DNA was digested with BglII, 
EcoRI, and NcoI or NaeI, NdeI, and NcoI for c-MYC or Oct3/4, respectively, 
overnight. Digested DNA fragments were separated on 0.8% agarose gel and 
transferred to a nylon membrane (GE Healthcare). The membranes were   
CD42b+ functional platelets (Fig. 6 G and Fig. 7 C), as com-
pared with the numbers seen with continuous c-MYC O/E 
until day 26. We therefore conclude that increased expression 
of c-MYC in hematopoietic progenitors may promote mega-
karyopoiesis, leading to increased MK generation (Fig. 6 E), 
but that a sustained increase in c-MYC after the MK progeni-
tor stage may impair MK maturation, thereby diminishing 
platelet release (Fig. 6, F and G).
Both hESCs and hiPSCs were previously shown to differ-
entiate into hematopoietic cells (Wang et al., 2004; Vodyanik 
et al., 2005; Ma et al., 2008; Choi et al., 2009;  Yokoyama et al., 
2009), although with the exception of hESC-derived natural 
killer cells (Woll et al., 2009), only in vitro functionality has 
been reported. In this paper, we demonstrated that platelets 
derived from hiPSCs via a mechanism involving limited   
c-MYC reactivation (Fig. 4 B and Fig. 5 A) are capable of 
thrombus formation in vivo.
Recent studies suggest that the source of the somatic cells 
and introduction of reprogramming factors without c-Myc (ret-
roviral vectors, plasmids, proteins, Sendai viral vectors, and so 
on), also known as L-Myc/L-MYC, are essential elements for 
selection of efficient and safe iPSC clones (Okita et al., 2007; 
Nakagawa et al., 2010). We propose that selection of the iPSC 
clones most suitable for their purpose should also be consid-
ered. Our analysis of multiple hiPSC clones accompanied by Tg 
genome integration or a DOX-inducible expression system 
shows that time-dependent changes in c-MYC expression, spe-
cifically up-regulation and then down-regulation within an ap-
propriate time span, facilitates generation of a novel platelet 
transfusion system derived from hiPSCs. It is noteworthy that   
in vitro generation of platelet concentrates custom made from 
HLA-identical donors or the patients themselves are not sub-
ject to immune rejection and do not require donor blood.   
We propose that iPSC platelets could be an invaluable resource 
for patients requiring repeated platelet transfusion and that this 
system should enable us to investigate as yet unresolved aspects 
of the mechanisms underlying thrombocytopenia.
MATERIALS AND METHODS
Cells, reagents, viral vectors, and mice. All reagents were obtained from 
Sigma-Aldrich unless indicated otherwise. The human ESC clone Kyoto 
hESCs (KhES) 3 was obtained from the Institute for Frontier Medical Sci-
ence,  Kyoto  University  (Kyoto,  Japan)  after  approval  for  hESC  use  was 
granted by the Minister of Education, Culture, Sports, Science, and Technol-
ogy of Japan. PB was provided from healthy volunteers approved by ethical 
committee of the Institute of Medical Science at University of Tokyo for   
human sample-based experiments. The entire study using human samples 
was conducted in accordance with the Declaration of Helsinki. Animal ex-
periments and use of viral vectors were approved by the committees of the 
Institute of Medical Science and School of Medicine at University of Tokyo. 
pMX retroviral vectors were from T. Kitamura (The University of Tokyo, Tokyo, 
Japan). Original hiPSC clones, 201B6, 201B7, 253G1, and 253G4 (Kyoto 
University), were used as a reference (Takahashi et al., 2007). We established 
other hiPSC clones derived from HDFs (Cell Applications, Inc.) using a retro-
virus harboring four (OCT3/4, SOX2, KLF4, and c-MYC) or three (without 
c-MYC) reprogramming factors: TkDA3-1, -2, -4, -5, -9, and -20 and TkDN4-M 
clones. HDFs were cultivated in DME supplemented with 10% FBS, 2 mM 
l-glutamine, 100 U/ml penicillin, and 0.1 mg/ml streptomycin. All pluri-
potent cells were maintained as described previously (Takahashi et al., 2007).   2828 c-MYC modulates platelet generation from iPSCs | Takayama et al.
qRT-PCR. cDNA samples were prepared as described in the previous section. 
Real-time PCR was performed using a kit (TaqMan Gene Expression Master 
Mix [Applied Biosystems] or SYBR Premix Dimer Eraser [Takara Bio, Inc.]) 
according to the manufacturer’s instructions. Signals were detected using an 
ABI7900HT Real-Time PCR System (Applied Biosystems). Primer sets for 
GAPDH, c-MYC, p14ARF, p16INK4A, GATA-1, 1-tubulin, and NF-E2 p45 
were determined using the Universal Probe Library Set for humans (https://
www.roche-applied-science.com/sis/rtpcr/upl/index.jsp?id=UP030000). 
Primer sets for exogenous OCT3/4, SOX2, KLF4, c-MYC, and endogenous   
c-MYC are listed in Table S1.
Electron microscopic observation of hiPSC-derived platelets. Plate-
let pellets were fixed with a mixture of 0.5% glutaraldehyde and 2% parafor-
maldehyde in 0.1 M phosphate buffer, pH 7.4, for 60 min at 4°C. After 
washing with phosphate buffer, the samples were post-fixed with 1% osmium 
tetroxide in phosphate buffer for 60 min on ice. After dehydration, samples 
on coverslips were infiltrated with and embedded in Epoxy resin. Ultrathin 
sections (60–80 nm thick) were cut and stained with 2% uranyl acetate in 
70% methanol and Reynolds’ lead citrate and observed in a transmission 
electron microscope (1200EX; JEOL) operating at 80 kV.
Flow cytometric analysis of platelets. Washed platelets were prepared as 
described previously (Takayama et al., 2008). The resultant platelet pellets were 
resuspended with PBS and stained with anti–human CD41a (integrin IIb/3 
complex)-APC, GPIX-FITC, GPIb, or CD9-PE for 30 min at room tem-
perature. The platelets were then diluted in 200 µl PBS and analyzed by flow 
cytometry. Platelet numbers were estimated using true count beads (BD).
In vitro functional analysis of platelets derived from human iPSCs. 
Collected platelets were resuspended in an appropriate volume of modified 
Tyrode-Hepes buffer (10 mM Hepes, pH 7.4, 12 mM NaHCO3, 138 mM 
NaCl, 5.5 mM glucose, 2.9 mM KCl, and 1 mM MgCl2) and eventually used 
after addition of 1 mM CaCl2. To investigate integrin IIb3 activation,   
50-µl aliquots of fresh PB- or PB-based aged, hESC-, and hiPSC-derived plate-
lets (ESC platelets and iPSC platelets) were incubated with PE-conjugated 
anti-GPIb and FITC-conjugated PAC-1 (Shattil et al., 1985) or FITC-con-
jugated CD62P (P-selectin) in the absence or presence of human thrombin 
or ADP for 20 min at room temperature. The binding of PAC-1 to platelets 
was quantified using an Aria flow cytometer. Nonspecific binding was deter-
mined in the presence of 10 µM tirofiban, a specific antagonist of human in-
tegrin IIb3 (Peerlinck et al., 1993). Specific binding was defined as total 
minus nonspecific binding.
In vivo imaging by iPSC-platelets. Details of this method are provided 
elsewhere (Nishimura et al., 2008; Takizawa et al., 2010). In brief, to visually 
analyze iPSC platelet function, including circulation and thrombus formation 
in the mesentery of living animals, mice were anesthetized and a small incision 
was made in the abdominal wall. Intravital imaging was then performed 
through this small (3 mm) window. FITC-dextran (20 mg/kg body weight) 
was injected into the tail vein for visualization of host blood cell dynamics. 
iPSC-derived platelets were stained with 5 µM TMRE for 15 min, washed, 
and injected into the mice. To induce thrombus formation, hematoporphyrin 
(1.8 mg/kg body weight) was also administrated. Sequential two-color images 
were obtained for 20 s at 30 frames/s using a high-speed spinning-disk confo-
cal laser scanning microscope (CSU-X1) and a pair of EM charge-coupled 
device cameras (iXon). All experiments were approved by the University of 
Tokyo Ethics Committee for Animal Experiments and strictly adhered to the 
guidelines for animal experiments of the University of Tokyo.
Statistical analysis. All data are presented as the mean ± SEM. We used 
two-tailed Student’s t tests for statistical analysis; values of P < 0.05 were con-
sidered significant.
Online supplemental material. Fig. S1 depicts the character of hiPSCs de-
rived from HDFs. Fig. S2 shows the generation of hematopoietic progenitors 
hybridized  with  radioactively  labeled  DNA  probes  (c-MYC-exon3  or 
Oct3/4-exon1) in PerfectHyb Plus Hybridization buffer (Sigma-Aldrich) at 
55°C overnight with constant agitation. After washing, signals were detected 
by the FLA-5100 imaging system (Fujifilm).
Hematopoietic differentiation of hiPSCs. To differentiate hiPSCs into 
hematopoietic cells, we used the same protocol we established with hESCs 
(Takayama et al., 2008). In brief, small clumps of hiPSCs (<100 cells treated 
with PBS containing 0.25% trypsin, 1 mM CaCl2, and 20% KSR) were trans-
ferred onto irradiated C3H10T1/2 cells and co-cultured in hematopoietic 
cell differentiation medium, which was refreshed every 3 d. On days 14–15 
of culture, the iPS-Sacs were collected into a 50-ml tube, gently crushed with 
a pipette and passed through a 40-µm cell strainer to obtain hematopoietic 
progenitors, which were transferred onto freshly irradiated feeder cells and 
cultured in differentiation medium established as previously in human ESCs 
(Takayama et al., 2008). The medium was refreshed every 3 d, and nonadher-
ent cells were collected and analyzed from days 22 to 38.
DOX-inducible c-MYC lentiviral vector. The c-MYC gene-inducible 
lentiviral vector was based upon LV-TRE-mOKS-Ubc-tTA-I2G (Kobayashi 
et al., 2010) and made by replacing the mOKS cassette with c-MYC gene.   
Viral supernatant was generated as previously described (Eto et al., 2007).
Western blotting analysis. Experiments were performed as previously de-
scribed (Eto et al., 2007; Nishikii et al., 2008). In brief, 45 µg of cell lysates 
treated with TNE buffer (10 mM Tris-HCl, pH 7.8, 150 mM NaCl, 1%   
NP-40, and 1 mM EDTA), supplemented with protease inhibitor cocktail 
(Roche), were separated by electrophoresis on 10–20% SDS-polyacrylamide 
gradient gel (Bio-Rad Laboratories) and transferred to a polyvinylidine 
difluoride membrane (Millipore), followed by visualization with SuperSignal 
West Pico Chemiluminescent Substrate (Thermo Fisher Scientific).
Immunohistochemical  and  flow  cytometric  analyses  of  ES-  and 
iPS-Sacs. Immunohistochemical staining of iPS-Sacs was performed on day 
14 or 15. Intact iPS-Sacs were fixed with 10% methanol in PBS, after which 
they were stained first with an antibody against human VEGF-R2 and then 
with a secondary antibody and observed using an epifluorescence micro-
scope (DM IRBE; Leica). Round cells within the ES- and iPS-Sacs were 
stained  with  anti–human  CD31-PE,  CD34-FITC,  CD38-APC,  CD41a-
APC, CD45–Alexa Fluor 405, or VEGF-R2–APC antibodies and analyzed 
by flow cytometry.
Hematopoietic  colony-forming  cell  assay.  Hematopoietic  colony-
forming cell assays were performed in MethoCult H4434 semisolid medium 
(STEMCELL Technologies Inc.) supplemented with 50 ng/ml human TPO. 
10,000 hematopoietic progenitors from within an iPS-Sac were plated in 1.5 ml 
of medium and cultivated for 14 d. The colonies were then collected, stained 
with Hemacolor (Merck), and observed under a microscope.
Flow cytometric analysis of MKs. Nonadherent cells on days 22–38 
were prepared in PBS containing 2% FBS and stained with combinations of 
antibodies for 30 min on ice. Samples were then washed with PBS and ana-
lyzed by flow cytometry (FACSAria; BD).
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